- Date : 19/04/2023
- Read: 3 mins
Are you aware that Mankind Pharma offers premier healthcare brands such as Gas-O-Fast, Health OK, AcneStar, Manforce and Prega News? Read on for IPO details.
Mankind Pharma, the renowned pharmaceutical company with popular brands like Manforce and Prega News, has set its sights on a massive IPO that promises to shake up the industry. With a price band of Rs 1,026-1,080 per share and the potential to raise Rs 43,264 crore at the upper end, Mankind Pharma's public issue has investors and analysts buzzing excitedly. Let's dive into the details of this much-awaited IPO and see what it means for the company and its shareholders.
Objective of this Initial Public Offering (IPO)
As per the company's red-herring prospectus (RHP), the upcoming IPO will be a complete offer for sale (OFS) of 40,058,844 equity shares. Promoters and existing investors are divesting their stakes in the Delhi-based pharmaceutical company (Mankind Pharma) through this IPO. The face value of equity shares is INR 1 per share.
Prominent promoters/ investors offloading shares
During the upcoming IPO, the promoters of the Delhi-based pharmaceutical company, Ramesh Juneja, Rajeev Juneja, and Sheetal Arora, will be offloading 3,705,443, 3,505,149, and 2,804,119 equity shares, respectively. In addition to the promoters, several investors will also be divesting their stakes, including Cairnhill CGPE Limited (up to 2,623,863 equity shares), Cairnhill CIPEF Limited (17,405,559 equity shares), Link Investment Trust (up to 50,000 equity shares), and Beige Limited (up to 9,964,711 equity shares).
Complete Timeline for the IPO
- Subscription opens: April 25th, 2023
- Subscription ends: April 27th, 2023
- Basis of allotment: May 3rd, 2023
- Initiation of refunds: May 4th, 2023
- Credit of shares to Demat: May 8th, 2023
- IPO listing date: May 9th, 2023
How many lots/ shares can a retail investor apply for?
The minimum lot size for retail investors is 13, i.e. one lot, and the maximum is 14 lots, or 182 shares, with a total value of Rs 196,560.
IPO allocation details
Qualified institutional investors (QIBs), Non-institutional investors (NIIs) and retail investors can subscribe to 50%, 15% and 35%, respectively.
Who are Book Running Lead Managers and Registrars for the IPO?
IIFL Securities, Axis Capital, Kotak Mahindra Capital, Jefferies India and JP Morgan are Book Running Lead Managers for this issue.
KFin Technologies is the registrar for this issue.
About the company
Mankind Pharma is a pharmaceutical company that formulates, produces, and markets various pharmaceutical compositions across several therapeutic areas, including cardiovascular gastrointestinal, anti-diabetic, anti-infectives, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands, including Candiforce, Moxikind-CV, Manforce (Rx), Amlokind-AT, Unwanted-Kit, and Prega News.
For the fiscal year ending on March 31st, 2022, Mankind Pharma Limited reported operating revenues exceeding INR 500 crore. The company's EBITDA increased by 30.57% compared to the previous year, and its book net worth grew by 28.19%.
(Reference: https://www.tofler.in/mankind-pharma-limited/company/U74899DL1991PLC044843)
Mankind Pharma, a reputed pharma company, is set to launch an IPO to divest the stakes of its promoters and existing investors. The IPO is a complete offer for sale (OFS) of 40,058,844 equity shares, with a face value of INR 1 per share. The IPO subscription period is from April 25th to April 27th, with the allotment basis on May 3rd and refunds initiated on May 4th. The company's IPO will be managed by IIFL Securities, Axis Capital, Kotak Mahindra Capital, Jefferies India, and JP Morgan as book-running lead managers and KFin Technologies as registrar.
Mankind Pharma, the renowned pharmaceutical company with popular brands like Manforce and Prega News, has set its sights on a massive IPO that promises to shake up the industry. With a price band of Rs 1,026-1,080 per share and the potential to raise Rs 43,264 crore at the upper end, Mankind Pharma's public issue has investors and analysts buzzing excitedly. Let's dive into the details of this much-awaited IPO and see what it means for the company and its shareholders.
Objective of this Initial Public Offering (IPO)
As per the company's red-herring prospectus (RHP), the upcoming IPO will be a complete offer for sale (OFS) of 40,058,844 equity shares. Promoters and existing investors are divesting their stakes in the Delhi-based pharmaceutical company (Mankind Pharma) through this IPO. The face value of equity shares is INR 1 per share.
Prominent promoters/ investors offloading shares
During the upcoming IPO, the promoters of the Delhi-based pharmaceutical company, Ramesh Juneja, Rajeev Juneja, and Sheetal Arora, will be offloading 3,705,443, 3,505,149, and 2,804,119 equity shares, respectively. In addition to the promoters, several investors will also be divesting their stakes, including Cairnhill CGPE Limited (up to 2,623,863 equity shares), Cairnhill CIPEF Limited (17,405,559 equity shares), Link Investment Trust (up to 50,000 equity shares), and Beige Limited (up to 9,964,711 equity shares).
Complete Timeline for the IPO
- Subscription opens: April 25th, 2023
- Subscription ends: April 27th, 2023
- Basis of allotment: May 3rd, 2023
- Initiation of refunds: May 4th, 2023
- Credit of shares to Demat: May 8th, 2023
- IPO listing date: May 9th, 2023
How many lots/ shares can a retail investor apply for?
The minimum lot size for retail investors is 13, i.e. one lot, and the maximum is 14 lots, or 182 shares, with a total value of Rs 196,560.
IPO allocation details
Qualified institutional investors (QIBs), Non-institutional investors (NIIs) and retail investors can subscribe to 50%, 15% and 35%, respectively.
Who are Book Running Lead Managers and Registrars for the IPO?
IIFL Securities, Axis Capital, Kotak Mahindra Capital, Jefferies India and JP Morgan are Book Running Lead Managers for this issue.
KFin Technologies is the registrar for this issue.
About the company
Mankind Pharma is a pharmaceutical company that formulates, produces, and markets various pharmaceutical compositions across several therapeutic areas, including cardiovascular gastrointestinal, anti-diabetic, anti-infectives, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands, including Candiforce, Moxikind-CV, Manforce (Rx), Amlokind-AT, Unwanted-Kit, and Prega News.
For the fiscal year ending on March 31st, 2022, Mankind Pharma Limited reported operating revenues exceeding INR 500 crore. The company's EBITDA increased by 30.57% compared to the previous year, and its book net worth grew by 28.19%.
(Reference: https://www.tofler.in/mankind-pharma-limited/company/U74899DL1991PLC044843)
Mankind Pharma, a reputed pharma company, is set to launch an IPO to divest the stakes of its promoters and existing investors. The IPO is a complete offer for sale (OFS) of 40,058,844 equity shares, with a face value of INR 1 per share. The IPO subscription period is from April 25th to April 27th, with the allotment basis on May 3rd and refunds initiated on May 4th. The company's IPO will be managed by IIFL Securities, Axis Capital, Kotak Mahindra Capital, Jefferies India, and JP Morgan as book-running lead managers and KFin Technologies as registrar.
